Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2000-12-15
pubmed:abstractText
Parkinson's disease (PD), a neurological disease suited to gene therapy, is biochemically characterized by a severe decrease in the dopamine content of the striatum. One current strategy for gene therapy of PD involves local production of dopamine in the striatum achieved by inducing the expression of enzymes involved in the biosynthetic pathway for dopamine. We previously showed that the coexpression of tyrosine hydroxylase (TH) and aromatic-L-amino-acid decarboxylase (AADC), using two separate adeno-associated virus (AAV) vectors, resulted in more effective dopamine production and more remarkable behavioral recovery in 6-hydroxydopamine-lesioned parkinsonian rats, compared with the expression of TH alone. Not only levels of TH and AADC but also levels of tetrahydrobiopterin (BH4), a cofactor of TH, and GTP cyclohydrolase I (GCH), a rate-limiting enzymes for BH4 biosynthesis, are reduced in parkinsonian striatum. In the present study, we investigated whether transduction with separate AAV vectors expressing TH, AADC, and GCH was effective for gene therapy of PD. In vitro experiments showed that triple transduction with AAV-TH, AAV-AADC, and AAV-GCH resulted in greater dopamine production than double transduction with AAV-TH and AAV-AADC in 293 cells. Furthermore, triple transduction enhanced BH4 and dopamine production in denervated striatum of parkinsonian rats and improved the rotational behavior of the rats more efficiently than did double transduction. Behavioral recovery persisted for at least 12 months after stereotaxic intrastriatal injection. These results suggest that GCH, in addition to TH and AADC, is important for effective gene therapy of PD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1043-0342
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1509-19
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10945765-Animals, pubmed-meshheading:10945765-Aromatic-L-Amino-Acid Decarboxylases, pubmed-meshheading:10945765-Biopterin, pubmed-meshheading:10945765-Cell Line, pubmed-meshheading:10945765-Corpus Striatum, pubmed-meshheading:10945765-Dependovirus, pubmed-meshheading:10945765-Dopamine, pubmed-meshheading:10945765-GTP Cyclohydrolase, pubmed-meshheading:10945765-Gene Expression Profiling, pubmed-meshheading:10945765-Gene Therapy, pubmed-meshheading:10945765-Gene Transfer Techniques, pubmed-meshheading:10945765-Genetic Vectors, pubmed-meshheading:10945765-Humans, pubmed-meshheading:10945765-Injections, pubmed-meshheading:10945765-Male, pubmed-meshheading:10945765-Motor Activity, pubmed-meshheading:10945765-Oxidopamine, pubmed-meshheading:10945765-Parkinson Disease, pubmed-meshheading:10945765-Rats, pubmed-meshheading:10945765-Rats, Wistar, pubmed-meshheading:10945765-Time Factors, pubmed-meshheading:10945765-Transformation, Genetic, pubmed-meshheading:10945765-Transgenes, pubmed-meshheading:10945765-Tyrosine 3-Monooxygenase
pubmed:year
2000
pubmed:articleTitle
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
pubmed:affiliation
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't